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OBJECTIVES This study compared rebound coagulation in patients with acute coronary syndrome patients
after discontinuation of unfractionated heparin (UFH) or low-molecular-weight heparin
(LMWH).
BACKGROUND Up to a quarter of patients hospitalized for unstable angina experience recurrent ischemia after
discontinuation of UFH or LMWH therapy, which may be the result of rebound coagulation
activation and subsequent thrombosis. It is unknown whether UFH and LMWH differ in
this respect.
METHODS We randomized 71 patients admitted with unstable angina to intravenous UFH or
subcutaneous LMWH (dalteparin) and measured plasma markers of coagulation before,
during, and after treatment.
RESULTS A complete series of measurements was obtained in 59 patients. Plasma prothrombin
fragment 12 (F12) levels decreased in both groups during treatment. After loss of
therapeutic plasma drug levels, F12 increased (within 3 h) to a maximum level at 12 to 24 h
that was higher than before or during treatment in both groups (p 0.0001). In both groups,
F12 levels remained higher than pretreatment up to 24 h after discontinuation. Similarly,
thrombin-antithrombin (TAT) levels exceeded treatment and pretreatment levels, at a slower
rate after dalteparin than after UFH. However, after dalteparin a higher peak value of TAT
was observed.
CONCLUSIONS Rebound coagulation activation occurs within hours after discontinuation of both UFH and
dalteparin. With both drugs, thrombin generation is significantly greater after treatment than
before or during treatment. A longer duration or weaning of treatment, or continuation with
another anticoagulant treatment, may reduce rebound coagulation activation and ischemic
events. (J Am Coll Cardiol 2002;39:811–7) © 2002 by the American College of Cardiology
Foundation
The medical treatment of patients with non–ST-segment
elevation acute coronary syndromes (ACS) includes short-
term intensive anticoagulant treatment for prevention of
thrombotic occlusion of the culprit coronary artery. Both
unfractionated heparin (UFH) and low-molecular-weight
heparin (LWMH) treatment result in a 60% reduction of
death or myocardial infarction during hospitalization as
compared to placebo (1–6). However, approximately 25%
of patients with ACS suffer from recurrent ischemic events
(death, infarction or need for urgent revascularization)
during the first 30 days after hospital admission (1–4).
Several studies indicate clustering of these events shortly
after cessation of UFH (7–11). In the Global Utilization of
Streptokinase and tPA for Occluded Arteries (GUSTO I)
study (7), including patients with acute myocardial infarc-
tion, a marked clustering of reinfarctions was observed
within hours after discontinuation of UFH infusion. Clin-
ical evidence of rebound ischemia in patients with unstable
angina was first described by Theroux et al. (8). In a
substudy of the Efficacy and Safety of Subcutaneous Enox-
aparin in Non–Q-wave Coronary Events (ESSENCE) trial
(12), patients with ACS randomized to UFH or enoxaparin
treatment were monitored by continuous ST-segment reg-
istration during the first 48 h on treatment and the first 48 h
after treatment. Treatment discontinuation resulted in a
significant increase of ischemic episodes in both groups.
A plausible cause of these recurrent ischemic events after
cessation of heparin is reactivation of the coagulation
system. With the loss of therapeutic heparin levels, pro-
thrombotic factors such as thrombin and tissue factor in the
culprit lesion of the coronary artery could reactivate the
coagulation system, rapidly resulting in thrombus growth as
well as platelet recruitment with subsequent ischemia.
If rebound coagulation is responsible for recurrent isch-
emic events after UFH discontinuation, the more gradual
plasma clearance of LMWH in comparison with UFH
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might avoid or reduce this phenomenon. Clinically superior
results of LMWH over UFH in patients with ACS could
partially be based on such a difference (1–4). To date, a
rebound phenomenon has not been reported for LMWH.
Therefore, we performed a randomized study to deter-
mine whether rebound activation of coagulation occurs after
cessation of LMWH treatment, and whether this is differ-
ent from rebound phenomenon seen with UFH.
METHODS
Patient selection. Consecutive patients admitted to our
coronary care unit for non–ST-segment elevation ACS were
screened for eligibility. Inclusion criteria were rest angina of
at least 5 min in duration and either electrocardiogram
(ECG) changes compatible with acute ischemia (ST-
segment depression 0.1 mV in 2 contiguous leads,
T-wave inversion 0.1 mV, transient ST elevation or new
left bundle branch block), creatinine kinase-MB (CK-MB)
levels of at least twice the normal limit or a history of
documented coronary artery disease. Excluded were patients
with known coagulation disorders, using anticoagulant
agents or scheduled to be transferred before the end of the
study.
Informed consent was obtained from all patients. Ran-
domization was performed with sealed envelopes containing
treatment allocation. The study was approved by the Insti-
tutional Review Board of the Academic Medical Center in
Amsterdam.
Treatment. Unfractionated heparin treatment started with
an intravenous (IV) bolus of 5,000 U, followed by contin-
uous infusion to reach a partial thromboplastin time be-
tween 60 and 90 s (i.e., 2- to 2.5-fold increase of control
value). Low-molecular-weight heparin treatment consisted
of twice daily subcutaneous injections 120 IU/kg dalteparin
(Fragmin). All patients received aspirin 100 mg daily. By
protocol, patients were treated with study medication until
clinically stable, for at least 48 h from onset of treatment or,
if applicable, at least 48 h after catheterization.
Additional medication was left to the discretion of the
treating physician, but included beta-blockers and IV nitro-
glycerin. Patients underwent coronary angiography only if
they developed severe refractory ischemia.
Blood sampling. Blood samples were collected before start
of study medication, during steady-state anticoagulation (24
h after start of study medication) and at 0, 3, 6, 12, 24 and
48 h after loss of therapeutic levels of the respective
heparins. For patients treated with UFH, cessation of
treatment was defined as time of discontinuation of the
infusion. For patients treated with dalteparin, cessation of
treatment was defined as 12 h after the last subcutaneous
injection (Fig. 1).
Blood samples were obtained through an IV infusion
system that was distal to other systems and not used for
medication. At each sampling, the first 2 ml of blood was
discarded and 10 ml was collected in citrated Vacutainer
tubes (4.5 ml citrate sodium 0.105 M siliconated 1 to 10).
Blood was centrifuged at 3,000 rpm for 20 min at 6°C.
Plasma was separated, pooled and filled out in cryocups and
Abbreviations and Acronyms
ACS  acute coronary syndromes
APC  activated protein C
CK-MB  creatinine kinase-MB
ECG  electrocardiogram
F12  prothrombin fragment 12
IV  intravenous
LMWH  low-molecular-weight heparin
PAP  plasmin-antiplasmin complexes
TAT  thrombin-antithrombin complexes
TFPI  tissue factor pathway inhibitor
UFH  unfractionated heparin
Figure 1. Schematic anticoagulation levels of unfractionated heparin (UFH) and low-molecular-weight heparin and definition of discontinuation time point
for UFH and dalteparin. (a) last dose of dalteparin; (b) cessation of UFH, discontinuation time point; (c) discontinuation time point for dalteparin.
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frozen at 80°C until analysis was performed. These
procedures were completed within 1 h after blood sampling.
Assays. Quantification of prothrombin fragment 12
(F12), thrombin-antithrombin complexes (TAT) and
plasmin-antiplasmin complexes (PAP) was performed by
sandwich-type enzyme-linked immunosorbent assays
(Dade-Behring, Marburg, Germany). Upper normal values
of these markers were F12 1.6 nmol/l, TAT 4.6 g/l and
PAP 700 g/l.
Levels of heparin activity were determined by a microti-
terplate chromogenic anti-factor Xa activity assay (Chro-
mogenix) and calibrated against UFH or dalteparin.
Clinical outcome. Recurrent ischemic events during hos-
pitalization were classified as angina with ischemic ECG
changes, angina leading to angiography or revascularization,
reinfarction with CK-MB rise of at least twice the normal
limit and death.
Statistical analysis. To determine differences between time
points within a treatment group, a nonparametric related
samples test (Wilcoxon) was performed for each of the eight
time points relative to the preceding time point. For
comparisons between the UFH and dalteparin groups, a
nonparametric independent samples test (Mann-Whitney
U test) was calculated. All statistical analyses were per-
formed with SPSS 10.0.7 (Chicago, Illinois). To examine
the absolute change of a parameter after treatment cessation,
stop values were subtracted from the following values and
were analyzed using a nonparametric independent samples
test (Mann-Whitney U test).
No formal repeated measurement analyses could be per-
formed because the data were not normally distributed.
Patients were excluded from the analysis when more than
two blood samples were missing, unless this was due to the
occurrence of a recurrent ischemic event resulting in thera-
peutic intervention (angioplasty, restart of anticoagulation).
Highly elevated levels of F12, TAT and PAP were
considered as sampling errors with ex-vivo coagulation
activation and excluded from the analysis. Cut-off values for
F12 were 8 nmol/l; TAT 50 g/l and PAP 1,000 g/l.
This resulted in the exclusion of 1%, 6% and 6% of the total
F12, TAT and PAP samples, respectively.
RESULTS
Of 71 study patients, 38 were randomized to UFH and 33
to dalteparin. Twelve patients were not included in the
analysis because they had more than two missing blood
samples. The reasons for incomplete blood sampling were
transfer to other hospitals (n  4), continuation of open-
label UFH or LMWH due to angioplasty or planned
coronary artery bypass graft (n  6), at patient’s request
(n  1) or at doctor’s request (n  1).
Table 1 summarizes baseline characteristics of the 59
included patients. No significant differences between the
UFH and dalteparin groups were observed. Median dura-
tion of treatment from first through the last dose was 48 h
for UFH patients and 55 h for dalteparin patients. Patients
treated with UFH had median prothrombin times of 66 s at
24 h after start and 68 s immediately before discontinuation
of therapy. While on anticoagulant treatment six UFH and
seven dalteparin patients underwent coronary angioplasty,
after which treatment was continued for a median of 44 h.
Thrombin generation. On admission, but before study
medication was started, F12 plasma levels were comparable
in both groups (Fig. 2). During the first 24 h of treatment,
both UFH and dalteparin significantly decreased F12 levels
(p  0.02), although dalteparin resulted in a greater
decrease compared to UFH (p  0.002). At the end of the
treatment period, F12 levels in the dalteparin group were
not significantly different from those in the UFH (see time
point “stop”). No significant changes of F12 were observed
in the UFH group during the remaining treatment period.
In the UFH group, treatment cessation resulted in a rapid
increase of F12, from 0.74 nmol/l to 1.25 nmol/l 3 h after
stopping (p 0.001). This increase persisted through 6 and
12 h after stop and reached a maximum level of 1.48 nmol/L
at 12 h. Dalteparin cessation also resulted in an increase of
thrombin generation with similar time to peak levels at 12 h
(1.21 nmol/l) after cessation. Compared to UFH, F12
levels were lower at 3 and 6 h after of dalteparin (p  0.002
and p  0.02, respectively) and remained lower although
the 12, 24 and 48 h samples were not significantly different.
At 48 h after treatment discontinuation, F12 levels in both
groups were at a similar level. When we corrected for F12
measured at the stop time point, no differences in F12
generation between UFH and dalteparin were observed.
Both groups revealed significant increases of F12 levels
with a maximum increase of 0.52 nmol/l at 6 h in the UFH
group and of 0.61 nmol/l at 12 h in the dalteparin group
(both p  0.0001 compared to stop values).
Compared to pretreatment levels, both groups showed
increased F12 levels up to 24 h after treatment discontin-
uation (p  0.03).
Table 1. Baseline Characteristics
UFH
n (%)
Dalteparin
n (%)
Female/male 9/20 14/16
Age (yrs) 63 61
Weight (mean in kg) 83 78
Diabetes 7 (24) 7 (23)
Smoking 13 (45) 11 (37)
Previous hyperlipidemia 6 (21) 13 (43)
Previous hypertension 11 (38) 13 (43)
Previous stable angina 10 (34) 16 (53)
Previous unstable angina 9 (31) 14 (47)
Previous myocardial infarction 7 (24) 13 (43)
Previous angioplasty 6 (21) 12 (40)
Previous CABG 2 (7) 3 (10)
Previous aspirin use 14 (50) 21 (70)
Angioplasty during heparin treatment 6 (21) 7 (23)
Median administration of anticoagulant
treatment (h)
48 55
CABG  coronary artery bypass graft; UFH  unfractionated heparin.
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Thrombin-antithrombin complex formation. Figure 3
presents the median plasma levels of TAT in both groups.
Pretreatment levels were comparable in both groups (7.3 g/l
in UFH and 5.4 g/l in dalteparin). Dalteparin treatment
did not result in changes of TAT levels 24 h after treatment
start, whereas UFH treatment resulted in a level increase
from 7.3 g/l to 13.8 g/l (p  0.121), which was
significantly different between both groups (p  0.042).
Continuation of UFH treatment restored plasma TAT
levels similar to those in the dalteparin group at 48 h after
treatment start (7.2 g/l and 6.1 g/l, respectively, p 
0.3).
When treatment with UFH was stopped, a rapid increase
of TAT levels was observed at 3 h, reaching a maximum at
6 h after discontinuation (20.6 g/l). At 12, 24 and 48 h,
TAT levels decreased to 13.5 g/l, 12.2 g/l and 4.8 g/l,
respectively. In the dalteparin group, a slight increase was
observed 3 h after treatment stop, with a steep increase at 6
and 12 h to TAT levels of 15.2 g/l and 31.4 g/l,
respectively. At 24 h, TAT levels were similar in both
groups, and the 48 h levels were comparable with pretreat-
ment levels. Differences between UFH and dalteparin were
observed at 3 and 12 h after treatment stop (p  0.01 and
p 0.004, respectively). When we corrected for TAT levels
measured at the stop time point, only dalteparin differed
from UFH at the 12-h post-treatment time point (p 
0.01).
Fibrinolysis. Plasmin-antiplasmin levels, an indicator of
fibrinolytic system activity, are presented in Figure 4. Both
UFH and dalteparin effectively suppressed the generation of
PAP complexes, indicating a decrease in fibrinolysis during
treatment (p  0.001), which persisted until treatment
discontinuation. Cessation resulted in both groups to
marked and persistent increases of PAP levels that were still
Figure 2. Median plasma levels of prothrombin fragment 12 (F12) before, during, and after unfractionated heparin (UFH) and dalteparin treatment.
Black diamond  UFH; white square  dalteparin. Samples were obtained before treatment start (pre), 24 h after start (on), at discontinuation of UFH
or dalteparin treatment (stop) and at 3, 6, 12, 24 and 48 h after discontinuation of treatment (3, 6, 12, 24, 48, respectively). Interquartile range of the values
at the various time points was 0.75 for UFH and 0.56 for dalteparin.
Figure 3. Median plasma levels of thrombin-antithrombin complexes (TAT) before, during, and after unfractionated heparin (UFH) and dalteparin
treatment. Black diamond UFH; white square dalteparin. Samples were obtained before treatment start (pre), 24 h after start (on), at discontinuation
of UFH or dalteparin treatment (stop) and at 3, 6, 12, 24 and 48 h after discontinuation of treatment (3, 6, 12, 24, 48, respectively). Interquartile range
of the values at the various time points was 15.6 for UFH and 11.9 for dalteparin.
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rising at 48 h and were significantly higher than pretreat-
ment levels (p  0.02).
Anti-Xa levels. Anti-Xa levels, an indicator for heparin
activity, were measured at all time points and median values
and are presented in Figure 5. There was a significant
difference in anti-Xa levels during steady-state treatment
between dalteparin (0.74 U/ml) and UFH (0.30 U/ml)
treatment (p  0.004). At treatment stop, anti-Xa levels
were comparable, consistent with the assumption that 12 h
after the last subcutaneous injection of dalteparin, therapeu-
tic anticoagulation levels are still present. A more gradual
decline in anti-Xa levels was observed in the dalteparin
group, with anti-Xa levels at 3 and 6 h of 0.23 U/ml and
0.12 U/ml, respectively (p 0.0001 and p 0.26 compared
to UFH, respectively). Anti-Xa was nearly undetectable in
the UFH group 3 h after cessation of infusion (0.01 U/ml).
Clinical recurrent ischemic events. Seven patients expe-
rienced recurrent angina with ECG changes within 48 h
after treatment cessation (three UFH and four dalteparin
patients). All were event free during the treatment period.
In three patients, anticoagulation therapy was restarted, and
one urgent revascularization was performed. None of the
patients died or experienced a myocardial infarction during
the first 48 h after treatment, although one UFH patient
died later during hospitalization. Four of these seven pa-
tients showed F12 increases above the upper limit of
normal after discontinuation (1.6 nmol/l, median peak
level of 6.0 nmol/l) simultaneous or preceding it up to 6 h,
whereas 28 patients without recurrent angina also showed
increased F12 levels (median peak level of 2.2 nmol/l).
Elevated TAT levels (4.6 g/l) after discontinuation were
common in both groups (at least at one time point in all but
Figure 4. Median plasma levels of plasmin-antiplasmin (PAP) before, during, and after unfractionated heparin (UFH) and dalteparin treatment. Black
diamond  UFH; white square  dalteparin. Samples were obtained before treatment start (pre), 24 h after start (on), at discontinuation of UFH or
dalteparin treatment (stop) and at 3, 6, 12, 24 and 48 h after discontinuation of treatment (3, 6, 12, 24, 48, respectively). Interquartile range of the values
at the various time points was 269.2 for UFH and 292.0 for dalteparin.
Figure 5. Median plasma levels of anti-factor Xa (anti-Xa) before, during, and after unfractionated heparin (UFH) and dalteparin treatment. Black
diamond  UFH; white square  dalteparin. Samples were obtained before treatment start (pre), 24 h after start (on), at discontinuation of UFH or
dalteparin treatment (stop) and at 3, 6, 12, 24 and 48 h after discontinuation of treatment (3, 6, 12, 24, 48, respectively).
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one patient) and levels were similar in patients with and
without recurrent angina (median level of 33.4 g/l and
31.7 g/l, respectively).
DISCUSSION
This study demonstrates that rebound activation of the
coagulation system occurs after discontinuation of both
UFH and dalteparin treatment, and it is the first to compare
the two. We found that the time course and the magnitude
of this rebound phenomenon was not different for UFH and
dalteparin. The peak level of F12 observed after discontin-
uation of dalteparin compared to UFH was similar after
correction for stop F12 values, indicating similar absolute
increases of F12. After both treatments, a sharp increase in
thrombin formation and TAT complexes was observed.
This was also reflected in plasma PAP complexes, which
increased up to 48 h after termination of heparin adminis-
tration. Remarkably, levels of F12 and PAP remained
elevated at least 24 h after treatment was discontinued, and
these levels were significantly higher than levels before
treatment was started, suggesting a heparin-induced eleva-
tion of these markers.
Differences between UFH and dalteparin were evident
during treatment, when dalteparin was more effective in
decreasing F12 levels. Thrombin-antithrombin levels were
unaffected by dalteparin treatment, but in the UFH group a
significant increase was observed. In both groups PAP levels
decreased. The more effective suppression of F12 by
dalteparin is consistent with the higher level of anti-Xa
activity (Fig. 5). Stable UFH levels are usually not reached
within 24 h, whereas dalteparin results in predictable levels
immediately after treatment is started. This difference is
likely reflected in the amount of F12 formed. Although one
would expect TAT levels to show a similar pattern, no
change was observed with dalteparin treatment, whereas
UFH resulted in a rise of these complexes (Fig. 3). Al-
though subtherapeutic levels of anticoagulation will fail to
decrease TAT levels, this cannot explain the increase of the
plasma levels as seen in the UFH group. Therefore,
LMWH administration may affect TAT complex forma-
tion in a different way.
Our study was too small to detect clinical differences
between the treatment groups. There was no clear relation
between clinical recurrent angina and increases of F12 and
TAT. However, peak levels of F12 were higher in patients
with recurrent angina (6.0 nmol/l vs. 2.2 nmol/l), suggesting
that the magnitude of thrombin generation may contribute
to the recurrence of clinical ischemia.
Previous studies. Rebound thrombin generation after dis-
continuation of UFH has been investigated previously
(13–15). In a study by Granger et al. (13), UFH cessation
resulted in increases of both F12 and fibrinopeptide A at 3
to 6 h. Normalization of all markers to pretreatment levels
was observed, whereas we observed that only TAT levels
decreased to baseline values at 48 h after cessation. Becker et
al. (14) found increased thrombin generation as soon as 1 h
after UFH cessation and further increasing at 24 h. Other
studies have shown that coagulation parameters may remain
elevated during the weeks or even months after the onset
(and treatment) of ACS (16–18).
Thrombin generation observed after discontinuation of
heparin is not likely explained by returning to the natural
course of the disease. In a Fragmin and Fast Revascularisa-
tion during Instability in Coronary artery disease (FRISC)
substudy, placebo-treated patients showed no significant
changes in plasma F12 levels in the first five days after
admission (16).
Potential mechanisms. A state of hypercoagulability after
heparin treatment may be induced by tissue factor pathway
inhibitor (TFPI) depletion (19). This lipoprotein, bound to
endothelial cells, is a natural anticoagulant inhibiting both
factor Xa as well as the tissue factor/fVIIa/fXa complex.
Infusion of heparin releases TFPI from endothelial cells,
and continued administration of heparin may result in
depletion of this anticoagulant. We did not perform
endothelium-bound TFPI measurements because UFH bo-
luses are required for quantification of this protein. Second,
both UFH and LMWH inhibit the generation of activated
protein C (APC), resulting in low levels of this natural
anticoagulant during treatment (20). Cessation of anticoag-
ulation at low APC levels may promote rebound coagula-
tion.
It is conceivable that angioplasty would stabilize the
culprit lesion and thus prevent rebound phenomena. How-
ever, in our study, among 8 of 13 patients who underwent
angioplasty during treatment, discontinuation of therapy
resulted in an increase of F12 above 1.6 nmol/l, suggesting
that the intervention may not result in a different rebound
pattern.
Clinical implications. Rebound thrombotic phenomena
have important clinical implications (7–11). Several clinical
studies have investigated the effect of prolonged treatment
with either LWMH (2,3,4,21) or oral anticoagulant treat-
ment after ACS (22–24). In the FRISC II study, a subgroup
of patients with ACS who continued dalteparin treatment
up to 90 days after hospital discharge did not benefit from
this regimen compared to short-term dalteparin (21). How-
ever, when high risk patients were selected on the basis of
troponin T-levels and ST-segment shifts on admission, a
significant reduction of death alone or death and myocardial
infarction at 90 days was obtained (25). It is unclear if our
findings with dalteparin can be extrapolated to other
LMWHs. In clinical studies, differences in outcome have
suggested that LMWHs are not equally effective (1–4,21).
However, variations in the designs of the studies may
explain these differences, and a direct comparison is lacking.
There have been no observations on rebound coagulation
after discontinuation of other LMWHs.
A recent publication focused on long-term oral antico-
agulation in patients discharged after hospitalization for
ACS (23). In patients compliant with the medication, oral
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anticoagulants resulted in a reduction of the combined end
point cardiac death, myocardial infarction or stroke (risk
ratio 0.68, 95% confidence interval 0.48 to 0.95). Cessation
of oral anticoagulation did not result in a rebound of
ischemic events during one-month follow up.
Because aspirin has been shown to reduce rebound effects
(8), additional inhibitors of platelet function may further
reduce rebound thrombosis. However, of five patients in our
study who received a thienopyridine because of stent im-
plantation, two showed increases of F12 above normal
limits after discontinuation of heparin treatment.
Summary. Treatment with both UFH and dalteparin is
followed by reactivation of coagulation to levels higher than
before or during treatment, and persisting at least 48 h after
treatment discontinuation. In dalteparin-treated patients,
reactivation peak levels were not different from those seen
after discontinuation of UFH. Rebound thrombin genera-
tion in patients with unstable angina or myocardial infarc-
tion is likely the cause of clinical recurrent ischemia seen
shortly after treatment cessation.
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